Pathology Service Studies & Research Findings
Pathology Service Studies & Research Findings - Peter MacCallum Cancer Centre
|• Diagnostic molecular test development|
• Predicting response to hormonal and chemotherapy in patients with in situ and invasive breast cancer in the neoadjuvant setting
• Genotyping the AOCS cohort for BRCA status
• Mammographic density and breast cancer
• Familial breast cancer
• Genetic and epigenetic determinants of response to cancer therapy
• Profiling of DNA repair in cancer.
• Rapid high resolution melting assays for mutation and methylation detection
• Novel diagnostics via nanoscaled biosensors.
• Somatic DNA methylation and cancer predisposition.
• JAK 2 quantitation in myeloproliferative disorders and normal donors
• P53 mutation status in myeloma patients on new biological agents
• Coagulation assessments and biomarker development in myeloma
• Microparticle assessment as a thrombogenic marker in haematological and solid tumours
• Immunophenotyping as a response marker for MDS patients on demethylating agents
• P53 assessment in diffuse large cell lymphoma (ALLG clinical trial, substudy)
• C-Kit mutation assessment in CBF-AML (ALLG clinical trial, substudy)
|Professor Stephen Fox|
• Translational pathology
• Translational research in breast cancer
• Fat and Breast Cancer: Aromatase, p53 and HIF-1alpha
• Personalised breast cancer risk assessment for high risk women
• Family study of the genetic and environmental causes and outcomes of early-onset breast cancer
• Familial male breast cancer
• Biomarker Validation testing
• Ovarian cancer as related to germline BRCA1 and BRCA2 mutations.
Dr David Westerman
• Assessment of thrombogenic biomarkers including microparticle assessment in myeloma patients treated with IMIDS
• Assessment of the utility of P53 mutation testing in myeloma patients treated with IMIDS
• Immunophenotyping as a diagnostic method for MDS, and its utility as a predictor of disease response to new biological agents. One of these studies is linking with an ALLG phase II MDS treatment trial
• Utility of CD200 as a differentiator in the diagnosis of NHL
• Quantitative JAK2 assessment in myelofibrosis patients undergoing allografting
• Cost of blood and platelet studies –how much does it cost a hospital holistically to transfuse these cellular products
• Teasing out biological factors of CD20 positive myeloma.
• Is CD38 a predictor for indolent mantle cell lymphoma. Biological dissection of this cohort is being undertaken.
Dr Neil Came
• Immunohistochemical study of the plasma cell and B-lymphoid compartments in all cases of Waldenström Macroglobulinemia at PMCC and RMH
• Immunohistochemical and Flow Cytometretric Evaluation of CD5-negative B-cell Lymphoma.
• Phenotypic and Molecular Characterisation of Clonogenic Multiple Myeloma Precursor Cells (collaboration with HITRL).
• Plasma cell Immunophenotyping by Flow Cytometry.
• Validation of eight colour flow cytometry in leukaemia, MDS, lymphoma and myeloma.
Dr Alex Dobrovic
• Translational and clinical research into cancers including breast, lung, colorectal and urological cancers and haematological malignancies.
• Identification of predictive markers enabling appropriate stratification of patients for individualised treatment.
• Development of clinical diagnostics.
• Adoption of novel molecular platforms and methodologies for genetic and epigenetic analysis.